The corporate-backed genome editing technology developer Precision BioSciences, which was spun out of Duke University, floated in the middle of its range and is now valued at more than $780m.
Precision BioSciences, a US-based genome editing technology spinout of Duke University, raised more than $126m in its initial public offering last week.
The offering consisted of 7.9 million shares issued on the Nasdaq Global Select Market priced at $16.00 each, in the middle of its $15 to $17 range, valuing the company at approximately $784m.
Founded in 2006, Precision Bio is working on genome editing technology in order to create treatments for cancer and genetic diseases, and enhance food…
